RRM2 and colorectal carcinoma: In summary, this study demonstrates that MYBL2 is a newly found important TFs for RRM2 transactivation in CRC proliferation, it functions by forming a dynamic S-phase complex with TAF15 and MuvB components to promote the malignant aggressiveness, and thus a potential novel target for CRC inhibition.